Home > News > Advectus and Immune Announce Nano-Pharmaceutical Project Update
September 4th, 2003
Advectus and Immune Announce Nano-Pharmaceutical Project Update
Advectus Life Sciences Inc. announced today that it has acquired an option from Immune Network Ltd. which, if exercised, would give the Company an exclusive worldwide interest in a new nanotechnology-based formulation for the treatment of Alzheimer's disease based on compositions that penetrate the "blood-brain barrier" with existing drugs.
Novel stapled peptide nanoparticle combination prevents RSV infection, study finds April 17th, 2014
More effective kidney stone treatment, from the macroscopic to the nanoscale April 17th, 2014
High-temperature plasmonics eyed for solar, computer innovation April 17th, 2014
Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Champions Oncology, Inc. April 17th, 2014